BLAINJECTIONINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 37m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO QVANTIG is a fixed-dose combination of nivolumab, a PD-1 inhibitor, with hyaluronidase enzyme to enable subcutaneous administration. This formulation expands access to Bristol Myers Squibb's cornerstone immunotherapy by eliminating the need for intravenous infusion. The combination maintains nivolumab's mechanism while improving patient convenience and clinical workflow efficiency.
Growth
As a 2024 launch in growth phase, this product will demand robust commercial infrastructure and cross-functional teams to capture market adoption from existing IV nivolumab populations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig
Started Aug 2025
200 enrolled
Cancer
Why This Matters for Your Career
Bristol Myers Squibb is hiring 2 roles related to this product
Worked on OPDIVO QVANTIG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.